Not all sufferers with CLL demand therapy. Regardless of all current improvements, the iwCLL still recommends watchful observation for patients with asymptomatic disease.86 This suggestion is predicated on at the least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 Both equally trials concluded https://michaele208fpy7.blog4youth.com/profile